Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674206 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| SCHEMBL32674103 | 0.94 | ALDH1A1 (0.53) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| SCHEMBL16865202 | 0.89 | ALDH1A1 (0.49) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| SCHEMBL25213325 | 0.84 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL32674110 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| Hydrochloric Acid SCHEMBL32674229 | 0.80 | ALDH1A1 (0.49) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| SCHEMBL20725745 | 0.80 | ALDH1A1 (0.45) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| SCHEMBL16865155 | 0.79 | CYP17A1 (0.46) | ALDH1A1MAPK1KMT2ACYP17A1CYP19A1 | |
| SCHEMBL31268160 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HTR2CDDB1CRBNMAPK1 | |
| SCHEMBL28885351 | 0.78 | FABP7 (0.50) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025011494-A1 | CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE | 优领医药科技(香港)有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-4464704-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Acerand Therapeutics (Hong Kong) Limited (HK) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116425744-A | Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PARP1, PARP11, PARP15 | ALDH1A1 543/4885HTR2C 1705/4885DDB1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.